These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 32105625)

  • 1. Point-of-care HIV viral load testing combined with task shifting to improve treatment outcomes (STREAM): findings from an open-label, non-inferiority, randomised controlled trial.
    Drain PK; Dorward J; Violette LR; Quame-Amaglo J; Thomas KK; Samsunder N; Ngobese H; Mlisana K; Moodley P; Donnell D; Barnabas RV; Naidoo K; Abdool Karim SS; Celum C; Garrett N
    Lancet HIV; 2020 Apr; 7(4):e229-e237. PubMed ID: 32105625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protocol for a randomised controlled implementation trial of point-of-care viral load testing and task shifting: the Simplifying HIV TREAtment and Monitoring (STREAM) study.
    Dorward J; Garrett N; Quame-Amaglo J; Samsunder N; Ngobese H; Ngomane N; Moodley P; Mlisana K; Schaafsma T; Donnell D; Barnabas R; Naidoo K; Abdool Karim S; Celum C; Drain PK
    BMJ Open; 2017 Sep; 7(9):e017507. PubMed ID: 28963304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study.
    Sharma M; Mudimu E; Simeon K; Bershteyn A; Dorward J; Violette LR; Akullian A; Abdool Karim SS; Celum C; Garrett N; Drain PK
    Lancet HIV; 2021 Apr; 8(4):e216-e224. PubMed ID: 33347810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uptake of antiretroviral therapy and male circumcision after community-based HIV testing and strategies for linkage to care versus standard clinic referral: a multisite, open-label, randomised controlled trial in South Africa and Uganda.
    Barnabas RV; van Rooyen H; Tumwesigye E; Brantley J; Baeten JM; van Heerden A; Turyamureeba B; Joseph P; Krows M; Thomas KK; Schaafsma TT; Hughes JP; Celum C
    Lancet HIV; 2016 May; 3(5):e212-20. PubMed ID: 27126488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial.
    Korthuis PT; King C; Cook RR; Khuyen TT; Kunkel LE; Bart G; Nguyen T; Thuy DT; Bielavitz S; Nguyen DB; Tam NTM; Giang LM
    Lancet HIV; 2021 Feb; 8(2):e67-e76. PubMed ID: 33539760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial.
    Venter WDF; Moorhouse M; Sokhela S; Serenata C; Akpomiemie G; Qavi A; Mashabane N; Arulappan N; Sim JW; Sinxadi PZ; Wiesner L; Maharaj E; Wallis C; Boyles T; Ripin D; Stacey S; Chitauri G; Hill A
    Lancet HIV; 2019 Jul; 6(7):e428-e437. PubMed ID: 31202690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Point-of-care HIV viral load and targeted drug resistance mutation testing versus standard care for Kenyan children on antiretroviral therapy (Opt4Kids): an open-label, randomised controlled trial.
    Patel RC; Oyaro P; Thomas KK; Wagude J; Mukui I; Brown E; Hassan SA; Kinywa E; Oluoch F; Odhiambo F; Oyaro B; Kingwara L; Karauki E; Yongo N; Otieno L; John-Stewart GC; Abuogi LL
    Lancet Child Adolesc Health; 2022 Oct; 6(10):681-691. PubMed ID: 35987208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the management of pretreatment HIV drug resistance by oligonucleotide ligation assay: a randomised controlled trial.
    Chung MH; McGrath CJ; Beck IA; Levine M; Milne RS; So I; Andersen N; Dross S; Coombs RW; Chohan B; Yatich N; Kiptinness C; Sakr SR; Kiarie JN; Frenkel LM
    Lancet HIV; 2020 Feb; 7(2):e104-e112. PubMed ID: 31818716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acceptability of point-of-care viral load testing to facilitate differentiated care: a qualitative assessment of people living with HIV and nurses in South Africa.
    Msimango L; Gibbs A; Shozi H; Ngobese H; Humphries H; Drain PK; Garrett N; Dorward J
    BMC Health Serv Res; 2020 Nov; 20(1):1081. PubMed ID: 33239012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Community-based antiretroviral therapy versus standard clinic-based services for HIV in South Africa and Uganda (DO ART): a randomised trial.
    Barnabas RV; Szpiro AA; van Rooyen H; Asiimwe S; Pillay D; Ware NC; Schaafsma TT; Krows ML; van Heerden A; Joseph P; Shahmanesh M; Wyatt MA; Sausi K; Turyamureeba B; Sithole N; Morrison S; Shapiro AE; Roberts DA; Thomas KK; Koole O; Bershteyn A; Ehrenkranz P; Baeten JM; Celum C;
    Lancet Glob Health; 2020 Oct; 8(10):e1305-e1315. PubMed ID: 32971053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
    ; Carey D; Puls R; Amin J; Losso M; Phanupak P; Foulkes S; Mohapi L; Crabtree-Ramirez B; Jessen H; Kumar S; Winston A; Lee MP; Belloso W; Cooper DA; Emery S
    Lancet Infect Dis; 2015 Jul; 15(7):793-802. PubMed ID: 25877963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Task shifting of antiretroviral treatment from doctors to primary-care nurses in South Africa (STRETCH): a pragmatic, parallel, cluster-randomised trial.
    Fairall L; Bachmann MO; Lombard C; Timmerman V; Uebel K; Zwarenstein M; Boulle A; Georgeu D; Colvin CJ; Lewin S; Faris G; Cornick R; Draper B; Tshabalala M; Kotze E; van Vuuren C; Steyn D; Chapman R; Bateman E
    Lancet; 2012 Sep; 380(9845):889-98. PubMed ID: 22901955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simplifying TREAtment and Monitoring for HIV (STREAM HIV): protocol for a randomised controlled trial of point-of-care urine tenofovir and viral load testing to improve HIV outcomes.
    Bardon AR; Dorward J; Sookrajh Y; Sayed F; Quame-Amaglo J; Pillay C; Feutz E; Ngobese H; Simoni JM; Sharma M; Cressey TR; Gandhi M; Lessells R; Moodley P; Naicker N; Naidoo K; Thomas K; Celum C; Abdool Karim S; Garrett N; Drain PK
    BMJ Open; 2021 Oct; 11(10):e050116. PubMed ID: 34610939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.
    Kityo C; Mambule IK; Musaazi J; Sokhela S; Mugerwa H; Ategeka G; Cresswell F; Siika A; Kosgei J; Shah R; Naidoo L; Opiyo K; Otike C; Möller K; Kaimal A; Wambui C; Van Eygen V; Mohammed P; Addo Boateng F; Paton NI;
    Lancet Infect Dis; 2024 Oct; 24(10):1083-1092. PubMed ID: 38821073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protocol for a randomised feasibility study of Point-Of-care HIV viral load testing to Enhance Re-suppression in South Africa: the POwER study.
    Dorward J; Sookrajh Y; Ngobese H; Lessells R; Sayed F; Bulo E; Moodley P; Samsunder N; Lewis L; Tonkin-Crine S; Drain PK; Hayward G; Butler CC; Garrett N
    BMJ Open; 2021 Feb; 11(2):e045373. PubMed ID: 33593788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Financial incentives for achieving and maintaining viral suppression among HIV-positive adults in Uganda: a randomised controlled trial.
    Thirumurthy H; Ndyabakira A; Marson K; Emperador D; Kamya M; Havlir D; Kwarisiima D; Chamie G
    Lancet HIV; 2019 Mar; 6(3):e155-e163. PubMed ID: 30660594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial.
    Laurent C; Kouanfack C; Laborde-Balen G; Aghokeng AF; Mbougua JB; Boyer S; Carrieri MP; Mben JM; Dontsop M; Kazé S; Molinari N; Bourgeois A; Mpoudi-Ngolé E; Spire B; Koulla-Shiro S; Delaporte E;
    Lancet Infect Dis; 2011 Nov; 11(11):825-33. PubMed ID: 21831714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Financial incentives to promote retention in care and viral suppression in adults with HIV initiating antiretroviral therapy in Tanzania: a three-arm randomised controlled trial.
    Fahey CA; Njau PF; Katabaro E; Mfaume RS; Ulenga N; Mwenda N; Bradshaw PT; Dow WH; Padian NS; Jewell NP; McCoy SI
    Lancet HIV; 2020 Nov; 7(11):e762-e771. PubMed ID: 32891234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon.
    Calmy A; Tovar Sanchez T; Kouanfack C; Mpoudi-Etame M; Leroy S; Perrineau S; Lantche Wandji M; Tetsa Tata D; Omgba Bassega P; Abong Bwenda T; Varloteaux M; Tongo M; Mpoudi-Ngolé E; Montoyo A; Mercier N; LeMoing V; Peeters M; Reynes J; Delaporte E;
    Lancet HIV; 2020 Oct; 7(10):e677-e687. PubMed ID: 33010241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.